News

Ignore The Noise - Novo Nordisk Is A Clear Buy
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Novo Holdings appoints four new members to its Board of Directors further strengthening global perspectives and strategic capabilities
Novo Holdings is pleased to announce the appointments of Jun Sung Kim, Lars Green, N.P. "Narv" Narvekar and Torsten Sløk to its Board of Directors, effective May 14, 2025. These distinguished leaders ...
Fierce Pharma1d
Novo heads to regulators after Sogroya matches predecessor Norditropin in 3 pediatric growth disorders
With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...
STAT22h
Novo Nordisk strikes deal with Septerna to develop obesity pills
Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...
Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs
Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster ...
They’re the force behind Robin’s and Novo. How SLO County duo took on culinary scene
While married, then divorced, this couple has shared 46 years working at their successful SLO County restaurants.
Novo Insulin Pen Retreat Risks Drug Access to Kids with Diabetes, Report Says
Novo Nordisk A/S’s decision to stop making insulin pens will narrow treatment options for children with diabetes unless ...
Surgery Partners reiterates 2025 guidance, targets $3.3B–$3.45B revenue while expanding high acuity and de novo growth
Q1 2025 Management View CEO Eric Evans reported "first quarter net revenue of $776 million and adjusted EBITDA of $103.9 ...